Aclaris Therapeutics Inc
Ouvert
4.43 3.02
Résumé
Variation du prix de l'action
24h
Min
4.3
Max
4.53
Revenu | -29K -20M |
|---|---|
Ventes | 701K 2M |
BPA | -0.15 |
Marge bénéficiaire | -993.186 |
Employés | 69 |
EBITDA | -2.5M -22M |
Recommandations | Achat Fort |
|---|---|
Prévisions sur 12 Mois | +146.99% upside |
Prochains Résultats | 5 août 2026 |
|---|
Capitalisation Boursière | -24M 609M |
|---|---|
Ouverture précédente | 1.41 |
Clôture précédente | 4.43 |
Aclaris Therapeutics Inc Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
À Propos Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.